



When you need
to be sure

SGS Pharma - Clinical Research

DV04: Safety at a Glance: Enhancing Participant Monitoring in Oncology Trials with Data Visualisation

Health Inspired, Quality Driven.

Agnieszka Bel, Senior Data Management System and Process Coordinator
PHUSE US CONNECT 2026 | Austin, Texas | 22-26 March 2026




Disclaimer and disclosures

The views and opinions expressed in this presentation are those of the author and do not necessarily reflect the opinions of PHUSE members, respective companies or organizations.

Agenda



- 
- A vertical background image on the right side of the slide showing a close-up of a desk. It includes a laptop keyboard, a stethoscope, a pen, and medical charts with bar graphs and pie charts.
- 01 Introduction
 - 02 SGS solution – data visualisation tool
 - 03 Medical review strategy
 - 04 Advantages and limitations
 - 05 Conclusion

Agenda



- 01 **Introduction**
- 02 SGS solution – data visualisation tool
- 03 Medical review strategy
- 04 Advantages and limitations
- 05 Conclusion

Introduction

Oncology is the largest therapeutic area amongst clinical trials → ~25% of all studies*

- ! Complex trial design
- ! Strict eligibility criteria
- ! Participants
 - Compromised health
 - Susceptible to adverse events
 - Sensitive to interactions with concomitant medications
 - Prone to having abnormal assessment results



High data
volume and
complexity


**Important for patient safety, that
medics keep a close eye on the data**

- Disease history
- (Serious) Adverse Events, Dose-Limiting Toxicities
- Laboratory results
- Clinical assessments: vital signs, physical examination results, performance status, ...
- Procedures
- Study drug administration information
- Concomitant medications and supportive care
- Disease response and progression

Introduction


Need for an efficient review strategy

- Comprehensive data overview
- Allowing quick review of up-to-date study data
- Enabling reviewers to make sense out of high-volume, complex data



Directly
in EDC

- Limited cross-patient overview
- Limited cross-domain overview
- Not all data available (external vendor data)
- Time-consuming review



Programmed
reports/tables

- Source – data not always up-to-date
- Difficult to spot patterns / outliers
- Multiple large listings – time-consuming review



Agenda



- 01 Introduction
- 02 **SGS solution – data visualisation tool**
- 03 Medical review strategy
- 04 Advantages and limitations
- 05 Conclusion

SGS data visualisation: Tableau

-  User-friendly interface
-  Interactive and dynamic dashboards
-  Drag and drop interface – rapid prototyping
-  Flexible and customisable
-  Various data sources possible
-  Data protection / security – separate sites

Dashboards strategy



Standard

- Common scenarios
- Library
- Source: SDTM
- Quick set-up and availability



Custom

- Tailor-made
- Based on existing dashboard or a new dashboard
- Various data sources / formats

Domain-specific

- All subjects (+ filters)
- E.g. AE, LB, VS

Cross-domain


- All subjects / per subject
- Different domains (+ relationships)
- E.g. AE/CM/MH, AE/LB, TR/RS

Patient profile

- Per subject
- Timeline with multiple domains

Agenda



- 
- A vertical background image on the right side of the slide showing a close-up of a desk. It includes a laptop keyboard, a stethoscope, a pen, and a medical chart with a bar graph and a pie chart.
- 01 Introduction
 - 02 SGS solution – data visualisation tool
 - 03 **Medical review strategy**
 - 04 Advantages and limitations
 - 05 Conclusion

Medical review strategy – case oncology trial

Standard

Domain-specific

- Adverse events
- Medical history
- Concomitant medications
- Procedures
- Physical examination
- Lab results
- ECG
- Vital signs
- Study drug exposure

Cross-domain

- Adverse events / concomitant medications / medical history

Patient profile

- Timeline: AE, MH, CM, EX, EG, VS, LB

Medical review strategy – case oncology trial

Custom


Domain-specific

- Cardiovascular system results
- Performance status

Cross-domain

- Initial diagnosis and cancer history
- Waterfall plot (tumour results / disease response)
- Spider plot (tumour results / disease response)
- Swimmer plot (disease response / disposition events)

Domain-specific – Adverse Events Overview



Domain-specific – Adverse Events Overview

Adverse Event Overview

AE Incidence

AE Grading

AE relation

AE Action Taken

AE Occurrence

Subject Do... (All)

ARM ARM A SGSDUMMY 520MG - D...

SEX (All)

Race (All)

Study Site... (All)

Subject (All)

Dictionary... (All)

Reported T... (All)

Serious Y

Outcome (Multiple values)

Tox. Grade (Multiple values)

Special Int... (All)

DLT (All)

Rel. to D (All)

Rel. to T (All)

Rel. to R (All)

Act. D (All)

Act. T (All)

Act. R (All)

Number of Occurrences per Adverse Events SOC

Primary System Org...
Nervous system disorders
Psychiatric disorders
Vascular disorders
Renal and urinary disorde..
Musculoskeletal and conn..
Investigations
General disorders and ad..
Cardiac disorders

Number of Occurrences per Adverse Events Preferred Term

Dictionary-Derived T...
Hemiparesis
Supraventricular tachycar..
Seizure
Lipase increased
Insomnia
Hypertension
Fatigue
Confusional state
Back pain
Acute kidney injury

Number of Adverse Events per subject

TESTTRIAL-2048
TESTTRIAL-2049
TESTTRIAL-47
TESTTRIAL-100047

Subject	Reported Term for the Adverse Event	Dictionary-Derived Term	Body System or Organ Class	Standard Toxicity Grade	Concomitant or Additional Trtmnt Given	Serious Event	Congenital Anomaly or Birth Defect	Persist or Signif Disability/ Incapacity	Results in Death	Is Life Threatening	Requires or Prolongs Hospitalizat.	Other Medically Important Serious Eve..	Outcome of Adverse Event	Rel. to D
TESTTRIAL-100047	LIPASE INCREASE	Lipase increased	Investigations	3	Y	Y	N	N	N	N	Y	N	RECOVERED/RESOLVED	REASONABLE CAUSAL RE
TESTTRIAL-2048	ACUTE KIDNEY INJURY	Acute kidney injury	Renal and urinary disord..	3	N	Y	N	N	N	N	Y	N	RECOVERED/RESOLVED	NO REASONABLE CAUSAL
	FATIGUE	Fatigue	General disorders and ad..	3	N	Y	N	N	N	N	Y	N	RECOVERED/RESOLVED	REASONABLE CAUSAL RE
	MUSCLE WEAKNESS L-SIDE	Hemiparesis	Nervous system disorders	2	Y	Y	N	N	N	N	Y	N	RECOVERED/RESOLVED	REASONABLE CAUSAL RE
	SUPRAVENTRICULAR TACHYCARDIA	Supraventricular tachycar..	Cardiac disorders	3	Y	Y	N	N	N	N	Y	N	RECOVERED/RESOLVED	NO REASONABLE CAUSAL
	WORSENING HYPERTENSION	Hypertension	Vascular disorders	3	Y	Y	N	N	N	N	Y	N	RECOVERED/RESOLVED	NO REASONABLE CAUSAL
TESTTRIAL-2049	INSOMNIA	Insomnia	Psychiatric disorders	3	Y	Y	N	N	N	N	Y	N	NOT RECOVERED/NOT RE..	NO REASONABLE CAUSAL
	LEFT-SIDED WEAKNESS	Hemiparesis	Nervous system disorders	2	Y	Y	N	N	N	Y	Y	N	NOT RECOVERED/NOT RE..	NO REASONABLE CAUSAL
	SEIZURE	Seizure	Nervous system disorders	2	Y	Y	N	N	N	Y	Y	N	NOT RECOVERED/NOT RE..	NO REASONABLE CAUSAL
	WORSENING CONFUSION	Confusional state	Psychiatric disorders	2	Y	Y	N	N	N	N	Y	N	NOT RECOVERED/NOT RE..	NO REASONABLE CAUSAL
TESTTRIAL-47	BACK PAIN	Back pain	Musculoskeletal and con..	3	N	Y	N	N	N	N	Y	N	NOT RECOVERED/NOT RE..	NO REASONABLE CAUSAL

Reviewed N

11

To Query N

11

Queried N

11

Selected Subjects 8

Domain-specific – Lab Overview

This dashboard shows an overview of lab results.
Use the filters to select a specific lab test - category - spec - method. A range of results (%) can be filtered as well. This uses a minimum and maximum calculated of each result for every test across all subjects.
Clicking on a data point in the table will display a graphic overview of that test for a specific subject. Multiselect is also possible.

Subject Dosed?
(All)

Arm
(All)

Armrs
(All)

Sex
(All)

Race
(All)

Subject
(All)

Visit - Timepoint
(All)

Range Legend
HIGH
NORMAL
LOW

Change x-axis
Visit/Timepoint

Change y-axis
Std. Results

Test-Cat-Spec-Method
ALP-CHEMISTRY-SERUM


Mean Profile
Subjects and Mean Profile

Filter Results (%)
0.0 100.0

Range Indicator
(All)

Significant
(All)

Reviewed	
N	Y
817	1



Subject		Lbseq	Lbtest	Test-Cat-Spec-Method	Lborres	Lborresu	Lbstresc	Lbstresu	Lbstnrlo	Lbstnrhi	Lbnrind	Lbclsig	Lblobxfl	Visit - Timepoint	Lbdtc	Rev
SGSDUMMY-S001		30	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	12	U/L	68	U/L	35	104	LOW	Null	Y	DAY -1	2023-01-19T09:02:58	N
		31	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	11	U/L	68	U/L	35	104	LOW	Null	Null	DAY 1 - 10H	2023-01-20T19:02:28	N
		32	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	67	U/L	67	U/L	35	104	NORMAL	Null	Null	DAY 2 - 24H	2023-01-21T08:59:55	N
		35	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	65	U/L	65	U/L	35	104	NORMAL	Null	Null	DAY 22	2023-02-10T08:54:46	N
		33	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	81	U/L	81	U/L	35	104	NORMAL	Null	Null	DAY 4 - 72H	2023-01-23T09:01:41	N
		36	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	67	U/L	67	U/L	35	104	NORMAL	Null	Null	DAY 43	2023-03-03T08:45:02	N
		37	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	69	U/L	69	U/L	35	104	NORMAL	Null	Null	DAY 57	2023-03-17T09:04:35	N
SGSDUMMY-S002		34	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	68	U/L	68	U/L	35	104	NORMAL	Null	Null	DAY 8	2023-01-27T09:32:10	N
		29	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	3	U/L	57	U/L	35	104	LOW	Null	Null	SCREENING	2022-12-26T13:13:02	N
		30	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	120	U/L	120	U/L	35	104	HIGH	N	Y	DAY -1	2023-01-17T09:25:34	N
		31	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	118	U/L	118	U/L	35	104	HIGH	N	Null	DAY 1 - 10H	2023-01-18T18:49:57	Y
		32	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	121	U/L	121	U/L	35	104	HIGH	N	Null	DAY 2 - 24H	2023-01-19T08:44:39	N
		35	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	126	U/L	126	U/L	35	104	HIGH	Y	Null	DAY 22	2023-02-08T08:49:12	N
		33	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	115	U/L	115	U/L	35	104	HIGH	N	Null	DAY 4 - 72H	2023-01-21T08:36:31	N
		36	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	132	U/L	132	U/L	35	104	HIGH	Y	Null	DAY 43	2023-03-01T08:36:07	N
		37	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	127	U/L	127	U/L	35	104	HIGH	N	Null	DAY 57	2023-03-15T08:49:23	N
		34	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	131	U/L	131	U/L	35	104	HIGH	Y	Null	DAY 8	2023-01-25T08:47:19	N
		29	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	124	U/L	124	U/L	35	104	HIGH	N	Null	SCREENING	2022-12-26T14:02:54	N

Domain-specific – Lab Overview

This dashboard shows an overview of lab results.
Use the filters to select a specific lab test - category - spec - method. A range of results (%) can be filtered as well. This uses a minimum and maximum calculated of each result for every test across all subjects.
Clicking on a data point in the table will display a graphic overview of that test for a specific subject. Multiselect is also possible.

Subject Dosed?
(All)

Arm
(All)

Armrs
(All)

Sex
(All)

Race
(All)

Subject
(All)

Visit - Timepoint
(All)

Test-Cat-Spec-Method
ALP-CHEMISTRY-SERUM

Mean Profile
Subjects and Mean Profile

Filter Results (%)
0.0 100.0

Range Indicator
(All)

Significant
(All)

Reviewed
N Y
817 1

Range Legend
HIGH
NORMAL
LOW

Change x-axis
Visit/Timepoint

Change y-axis
Std. Results

Current Selection: ALP - Alkaline Phosphatase (U/L)

ALP-CHEMISTRY-SERUM

✓ Keep Only

Exclude

Subject: SGSDUMMY-S002

x-axis: DAY 22

Lbtest: Alkaline Phosphatase

Test-Cat-Spec-Method: ALP-CHEMISTRY-SERUM

Result: 126

Unit: U/L

Range Indicator: HIGH

Significant: Y

Baseline:

SCREENI.. DAY -1 DAY 1-10H DAY 2-24H DAY 3-48H DAY 4-72H DAY 8-PRE-D.. DAY 8 DAY 10 DAY 15-PRE-D.. DAY 17 DAY 22-PRE-D.. DAY 22 DAY 24 DAY 29-PRE-D.. DAY 31 DAY 36-PRE-D.. DAY 38-48H DAY 43 DAY 43-168H DAY 50 DAY 57 DAY 64 DAY 78 DAY 92

150

100

50

0

150

100

50

0

Subject SGSDUMMY-S001

Lbseq	Lbtest	Test-Cat-Spec-Method	Lborres	Lborresu	Lbstresc	Lbstresu	Lbstnrlo	Lbstnrhi	Lbnrind	Lbclsig	Lblobxfl	Visit - Timepoint	Lbdtc	Rev
30	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	12	U/L	68	U/L	35	104	LOW	Null	Y	DAY -1	2023-01-19T09:02:58	N
31	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	11	U/L	68	U/L	35	104	LOW	Null	Null	DAY 1 - 10H	2023-01-20T19:02:28	N
32	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	67	U/L	67	U/L	35	104	NORMAL	Null	Null	DAY 2 - 24H	2023-01-21T08:59:55	N
35	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	65	U/L	65	U/L	35	104	NORMAL	Null	Null	DAY 22	2023-02-10T08:54:46	N
33	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	81	U/L	81	U/L	35	104	NORMAL	Null	Null	DAY 4 - 72H	2023-01-23T09:01:41	N
36	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	67	U/L	67	U/L	35	104	NORMAL	Null	Null	DAY 43	2023-03-03T08:45:02	N
37	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	69	U/L	69	U/L	35	104	NORMAL	Null	Null	DAY 57	2023-03-17T09:04:35	N
34	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	68	U/L	68	U/L	35	104	NORMAL	Null	Null	DAY 8	2023-01-27T09:32:10	N

SGSDUMMY-S002

29	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	3	U/L	57	U/L	35	104	LOW	Null	Null	SCREENING	2022-12-26T13:13:02	N
30	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	120	U/L	120	U/L	35	104	HIGH	N	Y	DAY -1	2023-01-17T09:25:34	N
31	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	118	U/L	118	U/L	35	104	HIGH	N	Null	DAY 1 - 10H	2023-01-18T18:49:57	Y
32	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	121	U/L	121	U/L	35	104	HIGH	N	Null	DAY 2 - 24H	2023-01-19T08:44:39	N
35	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	126	U/L	126	U/L	35	104	HIGH	Y	Null	DAY 22	2023-02-08T08:49:12	N
33	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	115	U/L	115	U/L	35	104	HIGH	N	Null	DAY 4 - 72H	2023-01-21T08:36:31	N
36	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	132	U/L	132	U/L	35	104	HIGH	Y	Null	DAY 43	2023-03-01T08:36:07	N
37	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	127	U/L	127	U/L	35	104	HIGH	N	Null	DAY 57	2023-03-15T08:49:23	N
34	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	131	U/L	131	U/L	35	104	HIGH	Y	Null	DAY 8	2023-01-25T08:47:19	N
29	Alkaline Phosphatase	ALP-CHEMISTRY-SERUM	124	U/L	124	U/L	35	104	HIGH	N	Null	SCREENING	2022-12-26T14:02:54	N

cdisc

SGS

Cross-domain – AE/CM/MH

AE_CM_MH

AE_CM_EX

This dashboard shows an overview of all medical history, adverse events and concomitant medications.

Use the filters to select a specific subject or other parameter. You can click on parts of the tables to dynamically filter the other panes. Relrec links are taken into account.

Select Subject

SGSDUMMY-S002

Subject Information:

Armcd

Sex

Age

Race

A

F

49

WHITE

Serious

(All)

Relation

(All)

Action taken

NOT APPLICABLE

Show current/prior CM

(All)

Cmindc

(All)

CM Taken for AE?

(All)

Mhcat

(All)

Adverse Events

Subject	Aeser	Aedecod	Aeterm	Aeacn	Aerel	Aeout	Aetoxr	Aeser	Aesconq	Aesdisab	Aesdth	Aeshosp	Aeslife	Relrec
SGSDUMMY-S002	1	Headache	HEADACHE	NOT APPLICABLE	UNLIKELY RELATED	RECOVERED/RESOLVED	2	N	Null	Null	Null	Null	Null	?
	2	Headache	HEADACHE	NOT APPLICABLE	UNLIKELY RELATED	RECOVERED/RESOLVED	1	N	Null	Null	Null	Null	Null	?
	3	Headache	HEADACHE	NOT APPLICABLE	UNLIKELY RELATED	RECOVERED/RESOLVED	1	N	Null	Null	Null	Null	Null	?
	4	Diarrhoea	LOOSE STOOLS	NOT APPLICABLE	POSSIBLY RELATED	RECOVERED/RESOLVED	1	N	Null	Null	Null	Null	Null	?
	5	Dry skin	DRY SKIN	NOT APPLICABLE	DEFINITELY RELATED	RECOVERED/RESOLVED	1	N	Null	Null	Null	Null	Null	?
	6	Nausea	NAUSEA	NOT APPLICABLE	POSSIBLY RELATED	RECOVERED/RESOLVED	3	N	Null	Null	Null	Null	Null	?
	7	Nausea	NAUSEA	NOT APPLICABLE	POSSIBLY RELATED	RECOVERED/RESOLVED	4	Y	Null	Null	Null	Null	Null	?
	8	Tendon disorder	TENDINOPATHY LEFT ...	NOT APPLICABLE	UNLIKELY RELATED	RECOVERING/RESOLVING	2	N	Null	Null	Null	Null	Null	?

Concomitant Medication

Subject	Cmseq	Cmcat	Cmdecod	Cmtrt	Cmdose	Cmdostxt	Cmdosu	Cmindc	Cmdosfrq	Cmroute	Cmstdtc
SGSDUMMY-S002	6	PRIOR MEDICATION	COPPER	MITHRA SERT	1	Null	APPLICATIO..	AE	OTHER	INTRAUTERINE	2020-09
	4	PRIOR MEDICATION	COVID-19 VACCINE NRVV AD (CHADOX1..	ASTRAZENECA COVID-19 VACCINE	1	Null	SYRINGE	PROPHYL..	ONCE	INTRAMUSCULAR	2021-03-11
	5	PRIOR MEDICATION	COVID-19 VACCINE NRVV AD (CHADOX1..	ASTRAZENECA COVID-19 VACCINE	1	Null	SYRINGE	PROPHYL..	ONCE	INTRAMUSCULAR	2021-06-03
	1	PRIOR MEDICATION	COVID-19 VACCINE	COVID-19 VACCINATION	1	Null	SYRINGE	AE	ONCE	INTRAMUSCULAR	2021-06-15
	7	PRIOR MEDICATION	TOZINAMERAN	PFIZER COVID-19 VACCINE	1	Null	SYRINGE	AE	ONCE	INTRAMUSCULAR	2021-11-23
	3	PRIOR MEDICATION	ELASOMERAN	MODERNA COVID-19 VACCINE	1	Null	SYRINGE	AE	ONCE	INTRAMUSCULAR	2021-12-21
	9	PRIOR MEDICATION	DIENOGEST;ESTRADIOL VALERATE	QLAIRA	Null	UNK	TABLET	MEDICAL ..	QD1-21	ORAL	2023
	2	CONCOMITANT MEDICATION	PARACETAMOL	DAFALGAN	500	Null	mg	OTHER	ONCE	ORAL	2023-01-18T20:47
	8	PRIOR MEDICATION	ETHINYLESTRADIOL;LEVONORGESTREL	MICROGYNON	0.05	Null	mg	PROPHYL..	QD1-21	ORAL	2023-03
	10	CONCOMITANT MEDICATION	IBUPROFEN	IBUPROFEN	Null	200-250	mg	AE	TID	ORAL	Null

Medical History

Subject	Mhseq	Mhcat	Mhdecod	Mhterm	Mhbodsys	Mhstdtc	Relrec	Mhendtc	Mhstdy	Mhendy	N
SGSDUMMY-S002	2	SURGICAL HISTORY	Gastric banding	GASTRIC BANDING	Surgical and medical procedures	2002		2002	Null	Null	N
	1	SURGICAL HISTORY	Mammoplasty	BREAST REDUCTION	Surgical and medical procedures	2004		2004	Null	Null	N
	4	SURGICAL HISTORY	Hysterectomy	HYSTERECTOMY	Surgical and medical procedures	2018		2018	Null	Null	N
	3	SURGICAL HISTORY	Gastric bypass	GASTRIC BYPASS	Surgical and medical procedures	2019		2019	Null	Null	N

cdisc

SGS

Cross-domain – AE/CM/MH

AE_CM_MH

AE_CM_EX

This dashboard shows an overview of all medical history, adverse events and concomitant medications. Use the filters to select a specific subject or other parameter. You can click on parts of the tables to dynamically filter the other panes. Relrec links are taken into account.

Select Subject

SGSDUMMY-S002

Subject Information:

Armcd

Sex

Age

Race

A

F

49

WHITE

Serious

(All)

Relation

(All)

Action taken

NOT APPLICABLE

Show current/prior CM

CONCOMITANT MEDICATION

Cmindc

OTHER

CM Taken for AE?

Y

Mhcat

(All)

Adverse Events

Subject	Aeser	Aeacod	Aeterm	Aeacn	Aerel	Aeout	Aetoxr	Aeser	Aescon	Aesdis	Aesdth	Aeshosp	Aeslife	
SGSDUMMY-S002	1	Headache	HEADACHE	NOT APPLICABLE	UNLIKELY RELATED	RECOVERED/RESOLVED	2	N	Null	Null	Null	Null	Null	?
	2	Headache	HEADACHE	NOT APPLICABLE	UNLIKELY RELATED	RECOVERED/RESOLVED	1	N	Null	Null	Null	Null	Null	?
	3	Headache	HEADACHE	NOT APPLICABLE	UNLIKELY RELATED	RECOVERED/RESOLVED	1	N	Null	Null	Null	Null	Null	?
	4	Diarrhoea	LOOSE STOOLS	NOT APPLICABLE	POSSIBLY RELATED	RECOVERED/RESOLVED	1	N	Null	Null	Null	Null	Null	?
	5	Dry skin	DRY SKIN	NOT APPLICABLE	DEFINITELY RELATED	RECOVERED/RESOLVED	1	N	Null	Null	Null	Null	Null	?
	6	Nausea	NAUSEA	NOT APPLICABLE	POSSIBLY RELATED	RECOVERED/RESOLVED	3	N	Null	Null	Null	Null	Null	?
	7	Nausea	NAUSEA	NOT APPLICABLE	POSSIBLY RELATED	RECOVERED/RESOLVED	4	Y	Null	Null	Null	Null	Null	?
	8	Tendon disorder	TENDINOPATHY LEFT ...	NOT APPLICABLE	UNLIKELY RELATED	RECOVERING/RESOLVING	2	N	Null	Null	Null	Null	Null	?

Concomitant Medication


Subject	Cmse	Cocat	Cmdecod	Cmtrt	Cmdose	Cmdostxt	Cmdosu	Cmindc	Cmdosfra	Cmroute	Cmstdtc
SGSDUMMY-S002	2	CONCOMITANT MEDICATION	PARACETAMOL	DAFALGAN	500	Null	mg	OTHER	ONCE	ORAL	2023-01-18T20:47

RELREC



Medical History


Patient Profile



Cross-domain – Waterfall



Cross-domain – Spider




Tumour Count

10




Subject	Trseq	Trlinkid	Trtestcd	Trtest	Trstresc	Trstresu	Triobxfi	Trdtc	Visit	Trdy
SGSDUMMY-91045	1	T02	LDIAM	Longest Diameter	37	mm	Y	2024-05-16	SCREENING	-25
	2	T02	LDIAM	Longest Diameter	37	mm	Null	2024-08-06	DISEASE EVALUATION 1	58
	3	T02	LDIAM	Longest Diameter	45	mm	Null	2024-09-26	DISEASE EVALUATION 2	109
	4	T01	LPERP	Longest Perpendicular	15	mm	Y	2024-05-16	SCREENING	-25
	5	T01	LPERP	Longest Perpendicular	15	mm	Null	2024-08-06	DISEASE EVALUATION 1	58
	6	T01	LPERP	Longest Perpendicular	18	mm	Null	2024-09-26	DISEASE EVALUATION 2	109
	7	Null	PCBSD	Percent Change Baseline in Sum of Diam	0	%	Null	Null	DISEASE EVALUATION 1	Null
	8	Null	PCBSD	Percent Change Baseline in Sum of Diam	21	%	Null	Null	DISEASE EVALUATION 2	Null
	9	Null	PCNSD	Percent Change Nadir in Sum of Diam	0	%	Null	Null	DISEASE EVALUATION 1	Null
	10	Null	PCNSD	Percent Change Nadir in Sum of Diam	21	%	Null	Null	DISEASE EVALUATION 2	Null
	11	Null	SUMDIAM	Sum of Diameter	52	mm	Y	2024-05-16	SCREENING	-25
	12	Null	SUMDIAM	Sum of Diameter	52	mm	Null	2024-08-06	DISEASE EVALUATION 1	58
	13	Null	SUMDIAM	Sum of Diameter	63	mm	Null	2024-09-26	DISEASE EVALUATION 2	109
	14	NT01	TUMSTATE	Tumor State	PRESENT	Null	Y	2024-05-16	SCREENING	-25
	15	NT02	TUMSTATE	Tumor State	PRESENT	Null	Y	2024-05-16	SCREENING	-25
	16	NT01	TUMSTATE	Tumor State	PRESENT	Null	Null	2024-08-06	DISEASE EVALUATION 1	58

Cross-domain – Swimmer



Agenda



- 
- A vertical strip image on the right side of the slide showing a close-up of a desk. It includes a laptop keyboard, a stethoscope, a pen, and medical charts with bar graphs and pie charts.
- 01 Introduction
 - 02 SGS solution – data visualisation tool
 - 03 Medical review strategy
 - 04 **Advantages and limitations**
 - 05 Conclusion



Advantages

✓ Improved data presentation

- Complex data → clear, interactive visuals
- Overview of all subjects / per subject
- Filters

✓ Enhanced data review

- Easy detection of safety trends, issues, outliers
- Drill-down and cross-domain analysis
- Quicker decision making

✓ Trial progression follow-up

- Enrollment and disposition dashboards



Advantages

✓ Streamlining collaboration and meetings

- Sharing comments
- Separate study environments with fixed underlying data
- Integration of exported data / graphs for reports
 - e.g., safety meetings (SRC, DSMB,...)

✓ Quick implementation

- Standard dashboards

✓ Customisable

- Different data sources / formats
- Dashboards content, e.g. different disease evaluation criteria




Limitations

- Data displayed in dashboards is limited for size & clarity
- Full overview vs conciseness
 - Careful choice of dashboards
- Tracking of data changes
- Limitations in programming power
 - Data pre-processing needed for advanced calculations
- Dashboard set-up and validation might be complex
- More detailed overview of results with tabular data
- A combination of review systems might be needed

Agenda



- 
- A vertical background image on the right side of the slide showing a close-up of a desk. It includes a laptop keyboard, a stethoscope, a pen, and medical charts with bar graphs and pie charts.
- 01 Introduction
 - 02 SGS solution – data visualisation tool
 - 03 Medical review strategy
 - 04 Advantages and limitations
 - 05 **Conclusion**

Conclusion

- **Oncology – major and complex therapeutic area**
- **Need for comprehensive data review strategy**
 - Early detection & accurate evaluation of critical findings
 - Quick decision-making
- **Data visualisation dashboards facilitate data and safety review**
 - Tailored to oncology trials
 - Simplified data presentation
 - Enhanced insight into safety signals and trends
 - Time-effectiveness
 - Facilitated collaboration between stakeholders



Questions?

Contact us

Agnieszka Bel

✉ clinicalresearch@sgs.com

🌐 www.sgs.com/pharma

in sgs.com/linkedinpharma

👥 **Visit us at the SGS Booth**

